<p>聖地亞哥，2025 年 12 月 10 日（全球新聞稿）——Crinetics Pharmaceuticals, Inc.（納斯達克：CRNX）今天宣佈，在 2025 年 12 月 10 日，董事會薪酬委員會授予了非合格股票期權獎勵，購買其普通股總計 39,575 股，並向 9 名新非執行員工授予了總計 26,525 股限制性股票單位（“RSU”）獎勵，均根據 Crinetics Pharmaceuticals, Inc. 2021 年就業誘導激勵獎勵計劃（“2021 年誘導計劃”）進行。股票期權和 RSU 的授予是為了吸引員工與 Crinetics 簽訂僱傭合同，符合納斯達克上市規則 5635(c)(4)。</p>
<p>2021 年誘導計劃專門用於向之前不是 Crinetics 員工的個人授予股權獎勵，或在經過真實的非就業期後，作為吸引這些個人與 Crinetics 簽訂僱傭合同的誘因，符合納斯達克上市規則 5635(c)(4)。股票期權的行使價格為每股 48.06 美元，等於 2025 年 12 月 10 日 Crinetics 普通股在納斯達克全球精選市場的收盤價。股票期權所涉及的股份將在四年內歸屬，其中 25% 的股份將在適用歸屬開始日期的一週年紀念日歸屬，其餘股份將在之後的 36 個連續的相等月度分期中歸屬，前提是每位員工在這些歸屬日期繼續在 Crinetics 工作。RSU 將在四年內以相等的年度分期歸屬，從適用歸屬開始日期的一週年紀念日開始，同樣前提是每位員工在這些歸屬日期繼續在 Crinetics 工作。股票期權和 RSU 獎勵受 2021 年誘導計劃的條款和條件以及適用的股票期權獎勵協議或 RSU 獎勵協議的條款和條件的約束。</p>
<p><strong>關於 Crinetics Pharmaceuticals</strong></p>
<p>Crinetics Pharmaceuticals 是一家全球製藥公司，致力於通過以患者需求為基礎的科學，轉變內分泌疾病和內分泌相關腫瘤的治療。Crinetics 專注於發現、開發和商業化新療法，核心專長是利用小分子靶向 G 蛋白偶聯受體（GPCRs），這些小分子具有特定定製的藥理學和特性。</p>
<p>Crinetics 的主打產品 PALSONIFY™（paltusotine）是美國 FDA 批准的首個每日一次的口服治療方案，適用於對手術反應不足的成人肢端肥大症患者，或手術不適合的患者。Paltusotine 還在臨牀開發中，針對與神經內分泌腫瘤相關的類癌綜合症。Crinetics 的深厚管線包括 10 多個已披露的項目，其中包括晚期研究候選藥物 atumelnant，目前正在針對先天性腎上腺增生和 ACTH 依賴性庫欣綜合症進行晚期開發。其他發現項目涉及多種內分泌疾病，如神經內分泌腫瘤、格雷夫斯病（包括格雷夫斯甲狀腺功能亢進和格雷夫斯眼病，即甲狀腺眼病）、多囊腎病、甲狀旁腺功能亢進、糖尿病、肥胖症和 GPCR 靶向的腫瘤指徵。</p>
<p><strong>投資者：</strong></p>
<p>Gayathri Diwakar</p>
<p>投資者關係負責人</p>
<p>gdiwakar@crinetics.com</p>
<p>（858）345-6340</p>
<p><strong>媒體：</strong></p>
<p>Natalie Badillo</p>
<p>企業傳播負責人</p>
<p>nbadillo@crinetics.com</p>
<p>（858）450-6464</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01ETXpPU00zTXpFMk5EVTRJekl3T0RrNE1UVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01ETXpPU00zTXpFMk5EVTRJekl3T0RrNE1UVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTM0NDc1YzQtMjY2My00MGViLTg0NzktNjM4NjM1ZjE3MGNiLTExMDEzODYtMjAyNS0xMi0xMC1lbg==/tiny/Crinetics-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTM0NDc1YzQtMjY2My00MGViLTg0NzktNjM4NjM1ZjE3MGNiLTExMDEzODYtMjAyNS0xMi0xMC1lbg==/tiny/Crinetics-Pharmaceuticals-Inc-.png"/></p>

CRNX

<p>Crinetics Pharmaceuticals 宣佈根據納斯達克上市規則 5635(c)(4) 提供誘因獎勵，向新員工授予股票期權和限制性股票單位（RSUs），作為其 2021 年誘因計劃的一部分。股票期權的行使價格為 48.06 美元，並將在四年內逐步歸屬。Crinetics 專注於內分泌疾病的治療，並擁有豐富的項目管道，包括用於肢端肥大症的 PALSONIFY™ 和用於先天性腎上腺增生的 atumelnant</p>

<p>SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 39,575 shares of its common stock and granted an aggregate of 26,525 restricted stock unit (“RSU”) awards to 9 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>聖地亞哥，2025 年 12 月 10 日（全球新聞稿）——Crinetics Pharmaceuticals, Inc.（納斯達克：CRNX）今天宣佈，在 2025 年 12 月 10 日，董事會薪酬委員會授予了非合格股票期權獎勵，購買其普通股總計 39,575 股，並向 9 名新非執行員工授予了總計 26,525 股限制性股票單位（“RSU”）獎勵，均根據 Crinetics Pharmaceuticals, Inc. 2021 年就業誘導激勵獎勵計劃（“2021 年誘導計劃”）進行。股票期權和 RSU 的授予是為了吸引員工與 Crinetics 簽訂僱傭合同，符合納斯達克上市規則 5635(c)(4)。</p>
</div><p>The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $48.06 per share, which is equal to the closing price of Crinetics’ common stock on the Nasdaq Global Select Market on December 10, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee’s continued employment with Crinetics on such vesting dates. The RSUs will vest over four years in equal annual installments beginning on the one-year anniversary of the applicable vesting commencement date, also subject to each employee’s continued employment with Crinetics on such vesting dates. The stock option and RSU awards are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an applicable stock option award agreement or RSU award agreement covering the respective grant.</p>
<div class="lb-trans"><p>2021 年誘導計劃專門用於向之前不是 Crinetics 員工的個人授予股權獎勵，或在經過真實的非就業期後，作為吸引這些個人與 Crinetics 簽訂僱傭合同的誘因，符合納斯達克上市規則 5635(c)(4)。股票期權的行使價格為每股 48.06 美元，等於 2025 年 12 月 10 日 Crinetics 普通股在納斯達克全球精選市場的收盤價。股票期權所涉及的股份將在四年內歸屬，其中 25% 的股份將在適用歸屬開始日期的一週年紀念日歸屬，其餘股份將在之後的 36 個連續的相等月度分期中歸屬，前提是每位員工在這些歸屬日期繼續在 Crinetics 工作。RSU 將在四年內以相等的年度分期歸屬，從適用歸屬開始日期的一週年紀念日開始，同樣前提是每位員工在這些歸屬日期繼續在 Crinetics 工作。股票期權和 RSU 獎勵受 2021 年誘導計劃的條款和條件以及適用的股票期權獎勵協議或 RSU 獎勵協議的條款和條件的約束。</p>
</div><p><strong>About Crinetics Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>關於 Crinetics Pharmaceuticals</strong></p>
</div><p>Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals 是一家全球製藥公司，致力於通過以患者需求為基礎的科學，轉變內分泌疾病和內分泌相關腫瘤的治療。Crinetics 專注於發現、開發和商業化新療法，核心專長是利用小分子靶向 G 蛋白偶聯受體（GPCRs），這些小分子具有特定定製的藥理學和特性。</p>
</div><p>Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.</p>
<div class="lb-trans"><p>Crinetics 的主打產品 PALSONIFY™（paltusotine）是美國 FDA 批准的首個每日一次的口服治療方案，適用於對手術反應不足的成人肢端肥大症患者，或手術不適合的患者。Paltusotine 還在臨牀開發中，針對與神經內分泌腫瘤相關的類癌綜合症。Crinetics 的深厚管線包括 10 多個已披露的項目，其中包括晚期研究候選藥物 atumelnant，目前正在針對先天性腎上腺增生和 ACTH 依賴性庫欣綜合症進行晚期開發。其他發現項目涉及多種內分泌疾病，如神經內分泌腫瘤、格雷夫斯病（包括格雷夫斯甲狀腺功能亢進和格雷夫斯眼病，即甲狀腺眼病）、多囊腎病、甲狀旁腺功能亢進、糖尿病、肥胖症和 GPCR 靶向的腫瘤指徵。</p>
</div><p><strong>Investors:</strong></p>
<div class="lb-trans"><p><strong>投資者：</strong></p>
</div><p>Gayathri Diwakar</p>
<div class="lb-trans"><p>Gayathri Diwakar</p>
</div><p>Head of Investor Relations</p>
<div class="lb-trans"><p>投資者關係負責人</p>
</div><p>gdiwakar@crinetics.com</p>
<div class="lb-trans"><p>gdiwakar@crinetics.com</p>
</div><p>(858) 345-6340</p>
<div class="lb-trans"><p>（858）345-6340</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒體：</strong></p>
</div><p>Natalie Badillo</p>
<div class="lb-trans"><p>Natalie Badillo</p>
</div><p>Head of Corporate Communications</p>
<div class="lb-trans"><p>企業傳播負責人</p>
</div><p>nbadillo@crinetics.com</p>
<div class="lb-trans"><p>nbadillo@crinetics.com</p>
</div><p>(858) 450-6464</p>
<div class="lb-trans"><p>（858）450-6464</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01ETXpPU00zTXpFMk5EVTRJekl3T0RrNE1UVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMDMzOSM3MzE2NDU4IzIwODk4MTU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTM0NDc1YzQtMjY2My00MGViLTg0NzktNjM4NjM1ZjE3MGNiLTExMDEzODYtMjAyNS0xMi0xMC1lbg==/tiny/Crinetics-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YTM0NDc1YzQtMjY2My00MGViLTg0NzktNjM4NjM1ZjE3MGNiLTExMDEzODYtMjAyNS0xMi0xMC1lbg==/tiny/Crinetics-Pharmaceuticals-Inc-.png"/></p>

Crinetics Pharmaceuticals 宣佈根據納斯達克上市規則 5635(c)(4) 授予 2025 年 12 月的激勵性授予 | CRNX 股票新聞